Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0;
21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21
days in combination for the first 4 cycles, and then every 42 days. Disease will be assessed
every 2 cycles (6 weeks) from C3D1 by CT-scan (or MRI or bone scan, if relevant). Patients
still under treatment after 1 year may have tumor evaluation spaced out every 3 cycles